Literature DB >> 21653234

17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli.

Christine D Palmer1, Christy J Mancuso, Jerrold P Weiss, Charles N Serhan, Eva C Guinan, Ofer Levy.   

Abstract

Detection and clearance of bacterial infection require balanced effector and resolution signals to avoid chronic inflammation. Detection of GNB LPS by TLR4 on m induces inflammatory responses, contributing to chronic inflammation and tissue injury. LXs and Rvs are endogenous lipid mediators that enhance resolution of inflammation, and their actions on primary human m responses toward GNB are largely uncharacterized. Here, we report that LXA(4), LXB(4), and RvD1, tested at 0.1-1 μM, inhibited LPS-induced TNF production from primary human m, with ATL and 17(R)-RvD1, demonstrating potent inhibition at 0.1 μM. In addition, 17(R)-RvD1 inhibited LPS-induced primary human m production of IL-7, IL-12p70, GM-CSF, IL-8, CCL2, and MIP-1α without reducing that of IL-6 or IL-10. Remarkably, when stimulated with live Escherichia coli, m treated with 17(R)-RvD1 demonstrated increased TNF production and enhanced internalization and killing of the bacteria. 17(R)-RvD1-enhanced TNF, internalization, and killing were not evident for an lpxM mutant of E. coli expressing hypoacylated LPS with reduced inflammatory activity. Furthermore, 17(R)-RvD1-enhanced, E. coli-induced TNF production was evident in WT but not TLR4-deficient murine m. Thus, Rvs differentially modulate primary human m responses to E. coli in an LPS- and TLR4-dependent manner, such that this Rv could promote resolution of GNB/LPS-driven inflammation by reducing m proinflammatory responses to isolated LPS and increasing m responses important for clearance of infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653234      PMCID: PMC3157902          DOI: 10.1189/jlb.0311145

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  76 in total

1.  Electron microscopical study of Neisseria meningitidis releasing various amounts of free endotoxin.

Authors:  B M Andersen; F Skjørten; O Solberg
Journal:  Acta Pathol Microbiol Scand B       Date:  1979-04

Review 2.  2. Cytokines and chemokines.

Authors:  Larry C Borish; John W Steinke
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 3.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

4.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

5.  Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.

Authors:  Levente József; Christine Zouki; Nicos A Petasis; Charles N Serhan; János G Filep
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

6.  Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo.

Authors:  Siobhan Mitchell; Graham Thomas; Killeen Harvey; David Cottell; Keira Reville; Giovanni Berlasconi; Nicos A Petasis; Lars Erwig; Andrew J Rees; John Savill; Hugh R Brady; Catherine Godson
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

7.  Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

Authors:  Alan S Cross; Steven M Opal; John E Palardy; Joseph J Drabick; H Shaw Warren; Christian Huber; Pamela Cook; Apurba K Bhattacharjee
Journal:  Vaccine       Date:  2003-11-07       Impact factor: 3.641

8.  Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages.

Authors:  S Jonsson; D M Musher; A Chapman; A Goree; E C Lawrence
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

9.  Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation.

Authors:  Ofer Levy; Armando Teixeira-Pinto; Mark L White; Stephen F Carroll; Leslie Lehmann; David Wypij; Eva Guinan
Journal:  Pediatr Infect Dis J       Date:  2003-11       Impact factor: 2.129

Review 10.  Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Steven Opal; Pamela Cook; Joseph Drabick; Apurba Bhattacharjee
Journal:  Vaccine       Date:  2004-02-17       Impact factor: 3.641

View more
  28 in total

Review 1.  Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators.

Authors:  Eric L Campbell; Charles N Serhan; Sean P Colgan
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

2.  Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes.

Authors:  Zhen Gu; Gwyneth J Lamont; Richard J Lamont; Silvia M Uriarte; Huizhi Wang; David A Scott
Journal:  Innate Immun       Date:  2016-02-15       Impact factor: 2.680

Review 3.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

4.  Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes.

Authors:  Jesmond Dalli; Romain A Colas; Carolina Quintana; Diana Barragan-Bradford; Shelley Hurwitz; Bruce D Levy; Augustine M Choi; Charles N Serhan; Rebecca M Baron
Journal:  Crit Care Med       Date:  2017-01       Impact factor: 7.598

Review 5.  New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Mol Aspects Med       Date:  2017-09-01

6.  Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.

Authors:  M Codagnone; E Cianci; A Lamolinara; V C Mari; A Nespoli; E Isopi; D Mattoscio; M Arita; A Bragonzi; M Iezzi; M Romano; A Recchiuti
Journal:  Mucosal Immunol       Date:  2017-04-19       Impact factor: 7.313

7.  Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway.

Authors:  You Lu; Qingyu Xu; Guowen Yin; Weidong Xu; Hao Jiang
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

8.  Proresolving lipid mediators and diabetic wound healing.

Authors:  Jason Hellmann; Yunan Tang; Matthew Spite
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

9.  The Independent and Combined Effects of Omega-3 and Vitamin B12 in Ameliorating Propionic Acid Induced Biochemical Features in Juvenile Rats as Rodent Model of Autism.

Authors:  Hanan Alfawaz; Mona Al-Onazi; Sarah I Bukhari; Manal Binobead; Nashwa Othman; Norah Algahtani; Ramesa Shafi Bhat; Nadine M S Moubayed; Haya S Alzeer; Afaf El-Ansary
Journal:  J Mol Neurosci       Date:  2018-10-04       Impact factor: 3.444

Review 10.  Contributions of neutrophils to resolution of mucosal inflammation.

Authors:  Sean P Colgan; Stefan F Ehrentraut; Louise E Glover; Douglas J Kominsky; Eric L Campbell
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.